Literature DB >> 31409450

Relation of Testosterone Normalization to Mortality and Myocardial Infarction in Men With Previous Myocardial Infarction.

Olurinde A Oni1, Seyed Hamed Hosseini Dehkordi2, Mohammad-Ali Jazayeri2, Rishi Sharma1, Mukut Sharma1, Reza Masoomi2, Ram Sharma1, Kamal Gupta2, Rajat S Barua3.   

Abstract

The effect of normalization of serum testosterone levels with testosterone replacement therapy (TRT) in patients with a history of myocardial infarction (MI) is unknown. The objective of this study was to determine the incidence of recurrent MI and all-cause mortality in subjects with a history of MI and low total testosterone (TT) with and without TRT. We retrospectively examined 1,470 men with documented low TT levels and previous MI, categorized into Gp1: TRT with normalization of TT levels (n = 755) Gp2: TRT without normalization of TT levels (n = 542), and Gp3: no TRT (n = 173). The association of TRT with all-cause mortality and recurrent MI was compared using propensity score-weighted Cox proportional hazard models. All-cause mortality was lower in Gp1 versus Gp2 (hazard ratio [HR] 0.76, confidence interval [CI] 0.64 to 0.90, p = 0.002), and Gp1 versus Gp3 (HR 0.76, CI 0.60 to 0.98, p = 0.031). There was no significant difference in the risk of death between Gp2 versus Gp3 (HR 0.97, CI 0.76 to 1.24, p = 0.81). Adjusted regression analyses showed no significant differences in the risk of recurrent MI between groups (Gp1 vs Gp3, HR 0.79, CI 0.12 to 5.27, p = 0.8; Gp1 vs Gp2 HR 1.10, CI 0.25 to 4.77, p = 0.90; Gp2 vs Gp3 HR 0.58, CI 0.08 to 4.06, p = 0.58). In conclusion, in a large observational cohort of male veterans with previous MI, normalization of TT levels with TRT was associated with decreased all-cause mortality compared with those with non-normalized TT levels and the untreated group. Furthermore, in this high-risk population, TRT was not associated with an increased risk of recurrent MI. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31409450     DOI: 10.1016/j.amjcard.2019.07.019

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  4 in total

Review 1.  Relationships between endogenous and exogenous testosterone and cardiovascular disease in men.

Authors:  Arthi Thirumalai; Bradley D Anawalt
Journal:  Rev Endocr Metab Disord       Date:  2022-10-11       Impact factor: 9.306

2.  Health Outcomes Among Long-term Opioid Users With Testosterone Prescription in the Veterans Health Administration.

Authors:  Guneet K Jasuja; Omid Ameli; Joel I Reisman; Adam J Rose; Donald R Miller; Dan R Berlowitz; Shalender Bhasin
Journal:  JAMA Netw Open       Date:  2019-12-02

Review 3.  Cardiovascular risk and testosterone - from subclinical atherosclerosis to lipoprotein function to heart failure.

Authors:  Baris Gencer; Marco Bonomi; Maria Pia Adorni; Cesare R Sirtori; François Mach; Massimiliano Ruscica
Journal:  Rev Endocr Metab Disord       Date:  2021-02-22       Impact factor: 6.514

4.  Association Between Testosterone Treatment and Risk of Incident Cardiovascular Events Among US Male Veterans With Low Testosterone Levels and Multiple Medical Comorbidities.

Authors:  Molly M Shores; Thomas J Walsh; Anna Korpak; Chloe Krakauer; Christopher W Forsberg; Alexandra E Fox; Kathryn P Moore; Susan R Heckbert; Mary Lou Thompson; Nicholas L Smith; Alvin M Matsumoto
Journal:  J Am Heart Assoc       Date:  2021-08-21       Impact factor: 5.501

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.